Neurotoxicity of MPTP

Neuropathology

Volumn 21, Issue 4, 2001, Pages 323-332

  Fukuda, Takahiro ^a,b  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NONE   (Japan)

Author keywords

1 methyl 4 phenyl 1,2,3,6 tetrahydropyridine; Dopamine agonist; Levodopa; Monoamine oxidase inhibitor; Parkinson's disease; Parkinsonism; Rotenone

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; CARBIDOPA; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; MONOAMINE OXIDASE INHIBITOR;

APOPTOSIS; ARTICLE; BRAIN REGION; CLINICAL FEATURE; CONTROLLED STUDY; ENVIRONMENTAL FACTOR; HISTOPATHOLOGY; HUMAN; INDUSTRIALIZATION; LOCUS CERULEUS; NEUROPATHOLOGY; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PARKINSONISM; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SUBSTANTIA NIGRA;

ANIMALS; DISEASE MODELS, ANIMAL; DOPAMINE AGENTS; ENVIRONMENTAL POLLUTANTS; HUMANS; INSECTICIDES; MPTP POISONING; NEUROPROTECTIVE AGENTS; PARKINSONIAN DISORDERS;

EID: 0035706410     PISSN: 09196544     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1789.2001.00402.x     Document Type: Article

References (59)

1. Chronic parkinsonism secondary to intravenous injection of meperidine analogues
2. Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): Seven cases
3. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis
4. Selective accumulation of MPP+ in the substantia nigra: A key to neurotoxicity?
5. Potential bioactivation pathways for the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)
6. Active uptake of MPP+, a metabolite of MPTP, by brain synaptosomes
7. +) and its analogs with the rotenone/piericidin binding site of NADH dehydrogenase
8. Inhibition of mitochondrial respiration by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in mouse brain in vivo
9. Extensive loss of brain dopamine and serotonin induced by chronic administration of MPTP in the marmoset
10. Tyrosine hydroxylase-immunohistochemical study in the midbrain of experimental MPTP parkinsonism
11. Neuropathological study on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine of the crab-eating monkey
12. NACP/alpha-synuclein-positive filamentous inclusions in astrocytes and oligodendrocytes of Parkinson's disease brains
13. Alpha-synuclein in Lewy bodies
14. An electron microscopic study of MPTP-induced inclusion bodies in an old monkey
15. Cell death: The significance of apoptosis
16. Apoptosis is induced by 1-methyl-4-phenylpyridinium ion (MPP+) in ventral mesencephalic-striatal co-culture in rat
17. Apoptosis and DNA degradation induced by 1-methyl-4-phenylpyridinium in neurons
18. Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine
19. Cell death
20. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation
21. Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation
22. Apoptotic DNA fragmentation is detected by a semiquantitative ligation-mediated PCR of blunt DNA ends
23. Mitochondrial control of nuclear apoptosis
24. Properties of some nuclear nucleases of rat thymocytes and their changes in radiation-induced apoptosis
25. The release of cytochrome c from mitochondria: A primary site for Bcl-2 regulation of apoptosis
26. Excitotoxicity and nitric oxide in Parkinson's disease pathogenesis
27. The mechanism of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity: Role of intracellular calcium
28. Enhanced hydroxyl radical generation by 2′-methyl analog of MPTP: Suppression by clorgyline and deprenyl
29. L-Dopa: Selective toxicity for melanoma cells in vitro
30. Neurotoxicity of levodopa on catecholamine rich neurons
31. Dopamine induces apoptosis-like cell death in cultured chick sympathetic neurons-A possible novel pathogenetic mechanism in Parkinson's disease
32. Monoamine-induced apoptotic neuronal cell death
33. Dopamine-induced programmed cell death in mouse thymocytes
34. Preservation of the substantia nigra and locus ceruleus in a patient receiving levodopa (2 kg) plus decarboxylase inhibitor over a four year period
35. Long-term administration of L-Dopa does not damage dopaminergic neurons in the mouse
36. Chronic levodopa impairs morphological development of grafted embryonic dopamine neurons
37. Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones
38. Where do we stand on neuroprotection?
39. Pargyline prevents MPTP-induced parkinsonism in primates
40. Oxidation reactions in Parkinson's disease
41. A multi-center, double-blind, placebo-controlled trial of pergolide as an adjunct to sinemet in Parkinson's disease
42. Pramipexole, a dopamine D2 receptor agonist, decreases the extracellular concentration of dopamine in vivo
43. Bromocriptine protects mice against 6-hydroxydopamine and scavenges hydroxyl free radical in vitro
44. Scavenging effects of dopamine agonists on nitric oxide radicals
45. The functional anatomy of basal ganglia disorders
46. Prevention of transneuronal degeneration of neurons in the substantia nigra reticulata by ablation of the subthalamic nucleus
47. Subthalamic nucleus lesion in rats prevents dopaminergic nigral neuron degeneration after striatal 6-OHDA injection: Behavioral immunohistochemical studies
48. Effects of bromocriptine and/or L-DOPA on neurons in substantia nigra of MPTP-treated C57BL/6 mice
49. Selective inhibition of complex I by N-methylisoquinolinium ion and N-methyl-1,2,3,4-tetrahydroisoquinoline in isolated mitochondria prepared from mouse brain
50. Presence of tetrahydroisoquinoline and 2-methyl-tetrahydroquinoline in parkinsonian and normal human brains
51. The effect of 1,2,3,4-tetrahydroisoquinoline (TIQ) on mesencephalic dopaminergic neurons in C57BL6J mice: Immunohistochemical studies-tyrosine hydroxylase
52. A N-methyltransferase in human brain catalyses N-methylation of 1,2,3,4-tetrahydroisoquinoline into N-methyl-1,2,3,4-tetrahydroisoquinoline, a precursor of a dopaminergic neurotoxin, N-methylisoquinolinium ion
53. 2-Methyl-1,2,3,4-tetrahydroisoquinoline does dependently reduce the number of tyrosine hydroxylase-immunoreactive cells in the substantia nigra and locus ceruleus of C57BL/6J mice
54. Did Leonardo describe Parkinson's disease?
55. Did parkinsonism occur before 1817?
56. Paralysis agitans and levodopa in 'Ayurveda' ancient Indian medical treatise
57. Chronic systemic pesticide exposure reproduces features of Parkinson's disease